000			nab a22 7a 4500
999			_c17048 _d17048
003			PC17048
005			20221103135501.0
008			221103b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9443 _aRojo Conejo, Pablo _ePediatría
245	0	0	_aHCV treatment in children and young adults with HIV/HCV co-infection in Europe. _h[artículo]
260			_bJournal of virus eradication, _c2015
300			_a1(3):179-84..
500			_aFormato Vancouver: Turkova A, Giacomet V, Goetghebuer T, Miloenko M, Nicolini LA, Noguera Julian A et al. HCV treatment in children and young adults with HIV/HCV co-infection in Europe. J Virus Erad. 2015 Jul 1;1(3):179-84.
501			_aPMID: 27482410 PMC4946737
504			_aContiene 45 referencias
520			_aObjectives: To describe use of treatment for chronic hepatitis C virus (HCV) infection in HIV/HCV co-infected children and young people living in Europe and to evaluate treatment outcomes. Methods: HCV treatment data on children and young people aged <25 years with HIV/HCV co-infection were collected in a cohort collaboration of 11 European paediatric HIV cohorts. Factors associated with receipt of HCV treatment and with sustained virological response 24 weeks after treatment completion (SVR24) were explored. Results: Of 229 HIV/HCV co-infected patients, 22% had a history of AIDS and of 55 who were treated for HCV, 47 (85%) were receiving combined antiretroviral therapy. The overall HCV treatment rate was 24% (n=55) but it varied substantially between countries, with the highest rate being in Russia at 61% (30/49). Other factors associated with treatment receipt were older age [adjusted odds ratio (AOR) 5.24, 95% confidence interval (CI) 1.9-14.4, for 18-24-year-olds vs 11-17-year-olds, P=0.001] and advanced fibrosis (AOR 5.5, 95% CI 1.3-23.7; for ≥9.6 vs ≤7.2 kPa, P=0.02). Of 50 patients with known treatment outcomes, 50% attained SVR24. Of these, 16 (80%) had genotype (GT) 2,3 and 8 (29%) had GT 1,4 (P<0.001). After adjusting for genotype (GT 1,4 vs GT 2,3), females (P=0.003), patients with non-vertical HCV acquisition (P=0.002) and those with shorter duration of HCV (P=0.009) were more likely to have successful treatment outcomes. Conclusion: Only half of the HIV/HCV co-infected youth achieved an HCV cure. HCV treatment success appears to be lower in the context of HIV co-infection than in HCV mono-infection, underscoring the urgent need to speed up approvals of new direct-acting antiviral combinations in children.
710			_9446 _aServicio de Pediatría-Neonatología
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946737/ _yAcceso libre
942			_2ddc _cART _n0